98%
921
2 minutes
20
Background And Aims: Central venous obstruction (CVO) increases the complexity of pacing interventions, whether it be with device-associated symptomatic superior vena cava syndrome (SVCS), or by impeding new implants. Endovascular treatment involves the joint expertise of both cardiac pacing and vascular specialists. We report the outcomes of such procedures at our institution.
Methods: A single-center retrospective observational study, examining outcomes of joint pacing-vascular procedures for CVO. Cases were screened from an existing institutional database.
Results: There were 19 total cases. Two were new device implants where the novel "inside-out" procedure was utilized to establish access in SVCS, both with no complications. The remainder (n = 17) were transvenous lead extractions plus attempted recanalization of CVO using venoplasty with or without stenting. Transvenous devices were re-implanted in eight patients. Complete procedure success rate was 84%. There were two cases of pericardial effusion requiring pericardiocentesis, resulting in procedure abandonment. There was no in-hospital mortality and no cases of emergency sternotomy. Over mean follow-up of 28 months, 2/6 patients receiving venoplasty (33%) and 2/8 patients receiving stenting (25%) required re-intervention for symptomatic restenosis. Of the patients who were not re-implanted with a transvenous device following initially successful endovascular intervention (6/14), none had recurrence over the follow-up period.
Conclusion: Pacing interventions in SVCS carry a significant risk profile, requiring management by experienced operators in high-volume centers to maximize safety. Endovascular interventions have a significant recurrence rate, with up-front stenting potentially being superior. Our data suggests that those without re-implantation of transvenous leads may have better long term outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pace.70019 | DOI Listing |
BMJ Open
September 2025
Arrhythmia Center, Chinese Academy of Medical Sciences Fuwai Hospital, Beijing, China.
Objectives: To evaluate the efficacy and safety of adding Superior Vena Cava Isolation (SVCI) to Pulmonary Vein Isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (PAF).
Design: Systematic review and meta-analysis of randomised controlled trials (RCTs) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, supplemented with Trial Sequential Analysis (TSA) to assess evidence sufficiency.
Data Sources: We searched PubMed, EMBASE, the Cochrane Library (CENTRAL) and Web of Science for relevant studies published up to 13 July 2025.
Heart Fail Rev
September 2025
Division of Provincial Cardiology, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Chemotherapy-induced cardiomyopathy (CHIC) represents a growing clinical challenge due to the increasing use of cardiotoxic treatments. These therapies can lead to progressive myocardial dysfunction, ultimately resulting in heart failure. Cardiac resynchronization therapy (CRT) has been widely investigated in selected patients with chronic heart failure; however, those with CHIC remain underrepresented in CRT trials.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
September 2025
Pacing & Electrophysiology Unit, Cardiology Department, Coimbra's Hospital and University Center, Coimbra, Portugal.
Background: Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation (CA) for atrial fibrillation (AF), yet outcomes remain suboptimal in persistent AF patients. Ethanol infusion in the vein of Marshal (VoM), an embryological remnant implicated in AF pathogenesis, may enhance ablation efficacy.
Objective: To evaluate the effectiveness of VoM ethanol infusion in patients with persistent AF.
Struct Heart
September 2025
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
•Evaluated ChatGPT-4o and OpenEvidence for structural heart disease decision support.•Among the first to assess the use of artificial intelligence amid rising adoption of TriClip and EVOQUE for transcatheter tricuspid valve interventions.•ChatGPT-4o delivered more accurate responses and proved more clinically reliable.
View Article and Find Full Text PDFEur Heart J Qual Care Clin Outcomes
September 2025
Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany.
Aims: Patients with device-detected atrial fibrillation (DDAF) have a lower stroke risk than those with ECG-diagnosed AF, requiring careful evaluation of oral anticoagulation benefits vs. its inherent bleeding risk.
Methods And Results: An unmatched win ratio analysis was performed of the NOAH-AFNET 6 trial dataset, using components of the primary efficacy and safety outcomes of the trial.